The dipeptidyl peptidase-4 inhibitor vildagliptin has the capacity to repair β-cell dysfunction and insulin resistance

Hormone and Metabolic Research

Volumn 46, Issue 11, 2014, Pages 814-818

  Horie, A ^a   Tokuyama, Y ^b   Ishizuka, T ^c   Suzuki, Y ^d   Marumo, K ^a   Oshikiri, K ^a   Ide, K ^a   Sunaga, M ^a   Kanatsuka, A ^a  

^a Chiba Central Medical Center   (Japan)

^b Kashiwado Hospital   (Japan)

^c Sato Clinic Hemodialysis Center   (Japan)

^d ASAHI GENERAL HOSPITAL   (Japan)

Author keywords

first phase insulin secretion; glucagon like peptide 1; insulin sensitivity; insulin modified minimal model; type 2 diabetes mellitus

Indexed keywords

ADAMANTANE; C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN; NITRILE; PYRROLIDINE DERIVATIVE; VILDAGLIPTIN;

ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; DIET RESTRICTION; DRUG EFFECTS; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL; PATHOLOGY; SECRETION (PROCESS);

ADAMANTANE; AREA UNDER CURVE; C-REACTIVE PROTEIN; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; NITRILES; PYRROLIDINES;

EID: 84931035973     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1382015     Document Type: Article

References (33)

1. Kieffer T. J., McIntosh C. H., Pederson R. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagons like polypeptide 1 in vitro and in vivo by dipeptidyl peptidadase IV. Endocrinology: 1995; 136 3585 3596
2. MacDonald P. E., EL-Kholy W., Riedel M. J. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes: 2002; 51 03 S434 S442
3. Nauck M. A., El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagons-like peptide-1. Diabetologia: 2005; 48 608 611
4. Holst J. J., Deacon C. F. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia: 2005; 48 612 615
5. Antoine M., Husam G., Mehul V., Kelly G., Sanan A., Ajay C., Sandeep D., Paresh D. Sitagliptin exerts an antiinflammatory action. J Clin Endocrinol Metab: 2012; 97 3333 3341
6. Junichi M., Seigo S., Eiichi A., Satomi I., Hirofumi K., Keisuke O., Hirofumi M., Koichiro F., Eiichiro Y., Koichi K., Seiji H., Hideaki J., Hisao O. Dipeptydyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J: 2013; 77 1337 1344
7. Campos R. V., Lee Y. C., Drucker D. J. Divergent tissue-specific and developmental expression of receptors for glucagons and glucagons-like peptide-1 in the mouse. Endocrinology: 1994; 134 2156 2164
8. Bullock B. P., Heller R. S., Habener J. F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagons-like peptide-1 receptor. Endocrinology: 1996; 137 2968 2978
9. Gorrell M. D. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci: 2005; 108 277 292
10. Kos K., Baker A. R., Jernas M., Harte A. L., Clapham J. C., O'Hare J. P., Charlsson L., Kumar S., McTernan P. G. DPP-IV inhibition enhances the antilypolytic action of NPY in human adipose tissue. Diabetes Obes Metab: 2009; 11 285 292
11. Faber O. K., Hagen C., Binder C., Markussen J., Naithani V. K., Blix P. M., Kuzuya H., Horwitz D. L., Rubenstein A. H., Rossing N. Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Invest: 1978; 62 197 203
12. Kanatsuka A., Makino H., Sakurada M., Hashimoto N., Iwaoka H., Yamaguchi T., Taira M., Yoshida S., Yoshida A. First-phase insulin response to glucose in nonobese or obese subjects with glucose intolerance: Analysis by C-peptide secretion rate. Metabolism: 1988; 37 878 884
13. Kanatsuka A., Tokuyama Y., Nozaki O., Matsui K., Egashira T. Beta-Cell dysfunction in late-onset diabetic subjects carrying homozygous mutation in transcription factors NeuroD1 and Pax4. Metabolism: 2002; 51 1161 1165
14. Tokuyama Y., Sakurai K., Yagui K., Hashimoto N., Saito Y., Kanatsuka A. Pathophysiologic phenotypes of Japanese subjects with varying degrees of glucose tolerance: using the combination of C-peptide secretion rate and minimal model analysis. Metabolism: 2001; 50 812 818
15. Tokuyama Y., Matsui K., Egashira T., Nozaki O., Ishizuka T., Kanatsuka A. Five missense mutations in glucagon-like peptide1 receptor gene in Japanese population. Diabetes Res Clin Pract: 2004; 66 63 69
16. Yoshida Y., Hashimoto N., Tokuyama Y., Kitagawa H., Takahashi K., Yagui K., Kanatsuka A., Bujo H., Higurashi M., Miyazawa S., Yoshida S., Saito Y. Efects of weight loss in obese subjects with normal fasting plasma glucose of impaired glucose tolerance on insulin release and insulin resistance according to minimal model analysis. Metabolism: 2004; 53 1095 1100
17. Ferrannini D. T., Mari A. How to measure insulin sensitivity. J Hypertens: 1998; 16 895 906
18. Bergman R. N., Ider Y. Z., Bowden C. R., Cobell C. Quantitative estimation of insulin sensitivity. Am J Physiol: 1979; 236 E667 E677
19. The Guideline for Epidemiology Study in Japan. The Ministry of Health, Labor and Welfare. June 30, 2003 (Japanese)
20. Eaton R. P., Allen R. C., Schade D. S., Erickson K. M., Standefer J. Prehepatic insulin production in man: Kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab: 1980; 51 520 528
21. Cerasi E., Luft R., Efndic S. Decreased sensitivity of the pancreatic beta cell to glucose in prediabetic and diabetic patients. Diabetes: 1972; 21 224 234
22. Van Cauter E., Mestrez F., Sturis J., Polonsky K. S. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes: 1992; 41 368 377
23. Brunzell J. D., Robertson R. P., Lerner R. L., Hazzard W. R., Ensinck J. W., Bierman E. L., Porte D. Jr. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab: 1976; 42 222 229
24. Field J. B. Extraction of insulin by liver. Am J Physiol: 1979; 237 E185 E191
25. Kristina M. T., Jenny T., Brenda M., Jayalakshmi U., Fernando G., Santica M. M., Catherine E. W., Monica A. L., James E. F., Jens J. H., Carolyn F. D., Steven E. K. The dipeptidyl peptidase-4 inhibitor vildagliptin improves β-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care: 2008; 31 108 113
26. Shibasaki T., Takahashi H., Miki T., Sunaga Y., Matsumura K., Yamanaka M., Zhang C., Tamamoto A., Satoh T., Miyazaki J., Seino S. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. PNAS: 2007; 104 19333 19338
27. Zhang C., Katoh M., Shibasaki T., Minami K., Sunaga Y., Takahashi H., Yokoi N., Iwasaki M., Miki T., Seino S. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science: 2009; 325 607 610
28. Arakawa M., Mita T., Azuma K., Ebato C., Goto H., Nomiyama T., Fujitani Y., Hirose T., Kawamori R., Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagons-like peptide-1 receptor agonist, exendin-4. Diabetes: 2010; 59 1030 1037
29. Zubair S., Thomas K., Jeffrey D., Sonja H., Stefan L., Margriet O., Kristin E., Jean M. K., Mikael R., Stefan M., Franz-George H., Johannes R., Peter A., Henrike S., Juergen E. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation: 2011; 124 2338 2349
30. Daniela L., Susanne F., Nina W. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes: 2011; 60 1917 1925
31. Giuseppe D., Anna C., Ivano F., Fabrizio Q., Elena F., Lucio B., Aldo B., Davide R., Arrigo C., Pamela M. Effects of a combination of sitagliptin plus metformin vs. metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetes patients. Diabetes Res Clin Pract: 2012; 98 51 60
32. Giuseppe D., Arrigo C., Ivano F., Fabrizio Q., Anna C., Mario P., Angela D., Elena F., Pamela M. A Randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: A 3-Year Study. Diabetes Technol Ther: 2013; 15 214 222
33. Bo A., Giovanni P., James E. F., Anja S. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care: 2005; 28 1936 1940